Jacob Sands
YOU?
Author Swipe
View article: US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan
US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan Open
Summary Background Datopotamab deruxtecan (Dato-DXd) is an investigational antibody–drug conjugate that has shown promising results in phase III clinical trials of lung and breast cancers. Stomatitis is a common adverse event associated wi…
View article: Impact of timing of adjuvant chemotherapy on survival for early-stage node-negative small-cell lung cancer
Impact of timing of adjuvant chemotherapy on survival for early-stage node-negative small-cell lung cancer Open
View article: Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer Open
Tarlatamab is a bispecific T‐cell engager immunotherapy targeting delta‐like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi‐301 trial of tarlatamab for patients with previously treated small cel…
View article: Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study Open
PURPOSE Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NC…
View article: Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer Open
The study found that tarlatamab given every 2 weeks shrank SCLC in participants with SCLC who received previous treatments. Participants given the 10 mg tarlatamab dose had fewer side effects than those given the 100 mg tarlatamab dose.…
View article: 1463 Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008
1463 Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008 Open
View article: Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer
Practical Management of Adverse Events in Patients Receiving Tarlatamab, a DLL3-targeted Bispecific T-cell Engager Immunotherapy, for Previously Treated Small Cell Lung Cancer Open
Tarlatamab is a bispecific T-cell engager (BiTE ® ) immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated…
View article: Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Open
PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NS…
View article: Proceedings of the 1st biannual bridging the gaps in lung cancer conference
Proceedings of the 1st biannual bridging the gaps in lung cancer conference Open
Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immun…
View article: The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies Open
Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has shown promisi…
View article: 59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial
59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial Open
The phase III TROPION-Lung01 trial (NCT04656652) evaluated Dato-DXd, a TROP2-directed antibody-drug conjugate, in patients with previously treated advanced NSCLC. The study met its dual primary endpoint of progression-free survival (PFS) i…
View article: 214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774)
214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774) Open
SCLC is an aggressive disease with poor survival. Despite initial response to chemoradiation, most patients with LS-SCLC relapse. Between 85-96% of patients with SCLC have tumor expression of Delta-like ligand 3 (DLL3), a Notch ligand aber…
View article: Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma Open
Large-scale CGP can better characterize biologically distinct molecular subtypes in LCNEC. Further studies to define how these molecular subtypes may help inform treatment decisions in this complex and challenging malignancy are warranted.
View article: Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting Open
Extensive-stage small-cell lung cancer (ES-SCLC) is an aggressive disease with poor 5-year survival. The first-line standard-of-care for ES-SCLC is platinum plus etoposide, along with 1 of the immune checkpoint inhibitors atezolizumab or d…
View article: 702 Phase 1 study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer
702 Phase 1 study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer Open
Background Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Large Cell Neuroendocrine of the lung (LCNEC) are aggressive neuroendocrine carcinomas with an exceptionally poor prognosis.1 2 Although the majority of patients ex…
View article: P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) Open
View article: LBA92 Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
LBA92 Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study Open
View article: First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 Open
PURPOSE This first-in-human, dose-escalation and dose-expansion study evaluated the safety, tolerability, and antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2 (TROP2)–directed antibody-dru…
View article: TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC Open
Pembrolizumab monotherapy is a standard first-line treatment for PD-L1-high advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA). However, few patients experience long-term disease control, highlighting …
View article: Screening for Lung Cancer: An Expert Review
Screening for Lung Cancer: An Expert Review Open
The NCCN Guidelines for Lung Cancer Screening have evolved over time to reflect the latest evidence and expert consensus. These NCCN Guidelines have played a significant role in shaping clinical practice and policy, leading to increased pa…
View article: Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis Open
Background For patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care regimens without clear and established biomark…
View article: 58 Examining elevated TMB and clinical benefit of 1L immune checkpoint inhibitor in advanced NSCLC
58 Examining elevated TMB and clinical benefit of 1L immune checkpoint inhibitor in advanced NSCLC Open
Background For patients with advanced non-small cell lung carcinoma (NSCLC), immune check point inhibitor (ICPI) and chemotherapy (chemo)-ICPI represent 2 distinct first-line standard-of-care regimens without clear and established biomarke…
View article: The design and evaluation of hybrid controlled trials that leverage external data and randomization
The design and evaluation of hybrid controlled trials that leverage external data and randomization Open
Patient-level data from completed clinical studies or electronic health records can be used in the design and analysis of clinical trials. However, these external data can bias the evaluation of the experimental treatment when the statisti…
View article: NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022 Open
The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Gui…
View article: Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216) Open
ClinicalTrials.gov Identifier: NCT02194738.
View article: The Design and Evaluation of Hybrid Controlled Trials that Leverage External Data and Randomization
The Design and Evaluation of Hybrid Controlled Trials that Leverage External Data and Randomization Open
Patient-level data from completed clinical studies or electronic health records can be used in the design and analysis of clinical trials. However, these external data can bias the evaluation of the experimental treatment when the statisti…
View article: Vascular Invasion Identifies the Most Aggressive Histologic Subset of Stage I Lung Adenocarcinoma: Implications for Adjuvant Therapy
Vascular Invasion Identifies the Most Aggressive Histologic Subset of Stage I Lung Adenocarcinoma: Implications for Adjuvant Therapy Open
View article: Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Open
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent t…
View article: MA15.05 Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)
MA15.05 Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance) Open
View article: The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC Open